Primary Open-Angle Glaucoma

Young H. Kwon, M.D., Ph.D., John H. Fingert, M.D., Ph.D., Markus H. Kuehn, Ph.D., and Wallace L.M. Alward, M.D.

GLAUCOMA IS A CHRONIC, DEGENERATIVE OPTIC NEUROPATHY THAT can be distinguished from most other forms of acquired optic neuropathy by the characteristic appearance of the optic nerve. In glaucoma, the neuroretinal rim of the optic nerve becomes progressively thinner, thereby enlarging the optic-nerve cup. This phenomenon is referred to as optic-nerve cupping. Its cause is the loss of retinal ganglion cell axons, along with supporting glia and vasculature. The remaining neuroretinal rim retains its normal pink color. In other optic neuropathies, the optic-nerve tissue loses its pink color and cupping does not develop. A rare exception is arteritic anterior ischemic optic neuropathy, in which cupping can occur. Patients with glaucoma typically lose peripheral vision and may lose all vision if not treated.

Although glaucoma frequently occurs without an elevation of intraocular pressure, the disease is nonetheless classified according to anterior-segment variations that can elevate intraocular pressure. The anterior segment of the eye has its own circulatory system, which nourishes the crystalline lens and cornea, both of which lack a blood supply. Aqueous humor, produced by the ciliary body, circulates throughout the anterior chamber and drains through the trabecular meshwork in the iridocorneal angle, which is the angle formed by the iris and cornea (Fig. 1). Elevated intraocular pressure does not result from increased aqueous humor production but rather from reduced aqueous outflow.

The glaucomas are classified by the appearance of the iridocorneal angle. There are open-angle, closed-angle, and developmental categories, which are further divided into primary and secondary types. Primary open-angle glaucoma can occur with or without elevated intraocular pressure; the latter is sometimes called normal-tension glaucoma. Primary open-angle glaucoma includes both adult-onset disease (occurring after 40 years of age) and juvenile-onset disease (occurring between the ages of 3 and 40 years of age). Examples of secondary open-angle glaucomas include those associated with exfoliation or pigment-dispersion syndrome. Closed-angle glaucoma can be primary (e.g., pupillary block) or secondary (e.g., inflammatory or neovascular causes). Developmental forms of glaucoma include primary congenital glaucoma and glaucoma associated with syndromes (e.g., aniridia or the Axenfeld–Rieger syndrome). Primary open-angle glaucoma, the predominant form of glaucoma in Western countries, probably comprises several clinically indistinguishable diseases.

In this review, we discuss primary open-angle glaucoma, in which the iridocorneal angle is open (unobstructed) and normal in appearance but aqueous outflow is diminished. We discuss the clinical features of primary open-angle glaucoma and mechanisms of elevated intraocular pressure and optic-nerve damage. To illustrate the mechanisms of elevated intraocular pressure, we focus on mutations in the myocilin (MYOC) gene. Approximately 4% of cases of adult-onset primary open-angle glaucoma and more than 10% of juvenile-onset cases are
associated with MYOC mutations. These adult-onset cases feature an elevated intraocular pressure with resultant optic-nerve damage and visual loss, and they are clinically indistinguishable from cases of primary open-angle glaucoma in patients without MYOC mutations. To address the mechanisms of optic-nerve damage, we broaden the discussion to include primary open-angle glaucoma with elevated intraocular pressure, with or without MYOC mutations.

**CLINICAL FEATURES**

**EPIDEMIOLOGY AND RISK FACTORS**

Primary open-angle glaucoma is the second leading cause of blindness in the United States and the leading cause of blindness among black Americans. There is good evidence that black race, older age, elevated intraocular pressure, family history of primary open-angle glaucoma, myopia, and low diastolic perfusion pressure are risk factors for primary open-angle glaucoma. (Table 1). Among patients with an elevated intraocular pressure, a relatively thin central cornea is another major risk factor for the disease. Evidence for other risk factors (diabetes mellitus, elevated systolic blood pressure, and migraine, among others) is less consistent.

**CLINICAL PRESENTATION**

The main clinical features of primary open-angle glaucoma are an open iridocorneal angle and cupping of the optic-nerve head (or optic disk), with corresponding loss of visual field. Elevated intraocular pressure is not part of the clinical definition because primary open-angle glaucoma can occur when intraocular pressure is normal (typically 10 to 21 mm Hg). Nevertheless, elevated intraocular pressure is an important risk factor and is also considered to be a causative factor in glau-
coma; currently, it is the only modifiable causative factor. Many randomized clinical trials have shown that reducing intraocular pressure slows the onset and progression of glaucoma. Therefore, all current treatments of primary open-angle glaucoma are aimed at reducing intraocular pressure by medical or surgical means.

The Case Presentation recounts a typical presentation of primary open-angle glaucoma (see box for Case Presentation, and see Fig. 2 for examination results).

### MYOCILIN

**GENETIC FEATURES**

Juvenile-onset primary open-angle glaucoma is rare. It has the same clinical features as the adult-onset condition, except that in the juvenile-onset form the intraocular pressure is often extremely high (frequently >40 mm Hg). Large pedigrees with autosomal-dominant inheritance of juvenile-onset primary open-angle glaucoma have been reported, and analyses of genetic markers in such pedigrees have mapped a glaucoma-related gene to a region of chromosome 1q designated GLC1A. Subsequent linkage studies of other glaucoma pedigrees have mapped the chromosomal locations of 13 additional glaucoma-related genes (GLC1B through GLC1N).

The relevant gene at the GLC1A locus is MYOC (Online Mendelian Inheritance in Man number, 601652), which encodes the protein myocilin. Myocilin is produced in many tissues, including the ciliary body and trabecular meshwork, the two ocular tissues that regulate intraocular pressure.

### Table 1. Major Risk Factors Associated with Primary Open-Angle Glaucoma.

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Prevalence of Glaucoma</th>
<th>Relative Risk of Glaucoma*</th>
<th>Source of Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td>Rudnicka et al.8</td>
</tr>
<tr>
<td>Black</td>
<td>4.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White†</td>
<td>2.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>1.4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Older age</td>
<td></td>
<td></td>
<td>Rudnicka et al.8</td>
</tr>
<tr>
<td>Black</td>
<td>1.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White†</td>
<td>2.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>1.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elevated intraocular pressure</td>
<td></td>
<td></td>
<td>Sommer et al.9</td>
</tr>
<tr>
<td>&lt;15 mm Hg</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16–18 mm Hg</td>
<td>2.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19–21 mm Hg</td>
<td>2.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22–29 mm Hg</td>
<td>12.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30–34 mm Hg</td>
<td>39.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diastolic perfusion pressure (adjusted odds ratio):‡</td>
<td></td>
<td></td>
<td>Tielsch et al.10</td>
</tr>
<tr>
<td>≥50 mm Hg</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40–49 mm Hg</td>
<td>1.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30–39 mm Hg</td>
<td>2.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30 mm Hg</td>
<td>6.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family history in first-degree relative (adjusted odds ratio)</td>
<td></td>
<td></td>
<td>Tielsch et al.11</td>
</tr>
<tr>
<td>Myopia (adjusted odds ratio)</td>
<td></td>
<td></td>
<td>Mitchell et al.,12 Wong et al.13</td>
</tr>
<tr>
<td>Thin central cornea (hazard ratio per 40-μm decrease)</td>
<td></td>
<td></td>
<td>Gordon et al.14</td>
</tr>
</tbody>
</table>

* Data are relative risks unless otherwise specified.
† The category of white race includes Hispanics.
‡ Diastolic perfusion pressure is defined as diastolic blood pressure minus intraocular pressure.
The role of MYOC in the pathogenesis of the common, adult-onset form of primary open-angle glaucoma has been explored by testing large cohorts of patients for mutations. A variety of MYOC mutations have been detected in 3 to 5% of patients with adult-onset primary open-angle glaucoma in cohorts around the world.\(^3\)\(^{27-31}\) Mutations in MYOC are among the most common causes of inherited eye disease with a known molecular basis. Mutations in other genes, including OPTN (encoding optineurin) and WDR36 (encoding a T-cell activation WD repeat-containing protein), have also been studied as potential causes of primary open-angle glaucoma. OPTN, which is in the GLC1E locus, has been associated with a small fraction of cases of low-pressure glaucoma,\(^32\) but less is known about the role of WDR36, which is in the GLC1G locus.\(^33\) These genes have recently been reviewed elsewhere.\(^34\)

**EFFECT ON THE TRABECULAR MESHWORK**

Some MYOC mutations have been detected in a sufficient number of patients to allow identification of mutation-specific glaucoma phenotypes, including age at onset and maximum intraocular pressure.\(^35\)\(^36\) A central clinical feature of myocilin-associated glaucoma is elevated intraocular pressure, and some mutations cause higher intraocular pressure than others. Mutations associated with juvenile-onset primary open-angle glaucoma lead to the greatest elevations in intraocular pressure — often more than 40 mm Hg. Mutations associated with adult-onset primary open-angle glaucoma typically cause maximum pressures of 25 to 40 mm Hg.\(^31\)\(^35\) In patients with MYOC mutations, high intraocular pressure appears to be important not only for the onset of glaucoma but also for progression of the disease. These effects suggest that MYOC mutations encode a protein that causes microscopic abnormalities in the structures of an otherwise normal-appearing iridocorneal angle, especially the trabecular meshwork.

The function of myocilin is unknown. Analysis of its amino acid sequence has revealed functional domains, including a leucine zipper domain for protein–protein interactions and two domains that can influence protein localization. The N-terminal of myocilin has a signal sequence that targets proteins for secretion, whereas the last three amino acids at the C-terminal of myo-
cilin encode a sequence that directs intracellular proteins to peroxisomes.\textsuperscript{37} Wild-type myocilin protein is secreted, which suggests that the peroxisomal targeting sequence is not functional under normal circumstances. The vast majority of glaucoma-associated \textit{MYOC} mutations lie within a large segment of myocilin protein that is homologous to olfactomedin proteins, a family of secreted proteins with unknown function.\textsuperscript{31}

Myocilin has been detected in the trabecular meshwork, which is the principal structure of the eye that regulates intraocular pressure.\textsuperscript{25,38,39} It has also been found secreted in the growth medium of primary cultures of human trabecular-meshwork cells and in human and mouse aqueous humor, indicating that myocilin is secreted from trabecular-meshwork cells in vitro and that in vivo it is secreted from ocular tissues that may include the trabecular meshwork or ciliary body.\textsuperscript{38,40-42} Recombinant myocilin protein, myocilin in aqueous humor, and myocilin in medium from cultured cells can self-associate and form multimers.\textsuperscript{25,38,43}

**DECREASED SECRETION**

\textit{MYOC} mutations do not appear to cause glaucoma as a result of haploinsufficiency or overexpression. Deficiencies in myocilin production resulting from a hemizygous deletion\textsuperscript{44} or a presumed homozygous null mutation (i.e., Arg46Stop)\textsuperscript{45} do not cause glaucoma. Similarly, glaucoma does not develop in mice with overexpression of myocilin or with deficient myocilin production.\textsuperscript{46,47} These results suggest that disease-causing mutations alter the myocilin protein in such a way that it disrupts the regulation of intraocular pressure. Indeed, \textit{MYOC} mutations associated with glaucoma do alter the properties of the protein — disease-associated mutations reduce the solubility of myocilin in a detergent, whereas benign sequence
polymorphisms have no such effect. Glaucoma-associ-ated mutations also reduce the secretion of myocilin in vitro and in vivo. Secretion of myocilin is dramatically reduced in trabecular-meshwork cells cultured from patients with glaucoma-associated MYOC mutations.

Similarly, MYOC mutations greatly reduce the quantity of myocilin that is secreted into the aqueous humor, supporting the idea that failure to secrete myocilin is a central feature in the pathogenesis of myocilin-associated glaucoma (Fig. 3). MYOC mutations may prevent the secretion of myocilin by exposing a cryptic domain that directs proteins to peroxisomes, and there is evidence that mutant myocilin may be retained within the intracellular space by means of an abnormal association with proteins of the peroxisome-targeting system. Other studies in mice have shown that mutations in the murine myocilin gene (Myoc) can inhibit secretion of myocilin and cause some signs of glaucoma without a cryptic targeting domain. Regardless of the mechanism of retention, decreased secretion and increased accumulation of intracellular myocilin appear to be initial steps in the pathogenesis of myocilin-associated glaucoma.

![COLOR FIGURE](https://example.com/color-figure.png)

**Figure 3. Proposed Pathways for Normal Secretion of Myocilin into the Aqueous Humor and for Secretion Reduced by a MYOC Mutation.** In Panel A, wild-type myocilin protein (green symbols) is produced in the endothelial cells of the trabecular meshwork and passes through the secretory pathway to reach the extracellular space. In the first step in this process, messenger RNA (mRNA) is transcribed from the gene encoding myocilin (MYOC) and is delivered to ribosomes at the endoplasmic reticulum, where the mRNA directs the synthesis of myocilin. Next, transport vesicles convey myocilin to the cell membrane through the Golgi apparatus. These vesicles fuse with the cell membrane and release myocilin into the extracellular space and aqueous humor. Along the secretory pathway, molecules of myocilin may associate with each other and form multimers (dimers and tetramers are depicted).

In Panel B, heterozygous mutations of the MYOC gene are associated with an autosomal dominant form of glaucoma. The wild-type copy of MYOC encodes normal myocilin protein (green symbols), and the mutant MYOC copy encodes mutant myocilin protein (red symbols). Myocilin protein forms multimers that may be composed of both wild-type and mutant subunits. Secretion of mutant myocilin protein and multimers containing mutant subunits is greatly reduced, leading to the retention of the mutant protein in the endoplasmic reticulum and intracellular vesicles of trabecular-meshwork cells.
Injury or death of trabecular-meshwork cells has been implicated in the pathogenesis of open-angle glaucoma.\textsuperscript{51} Endothelial cells of the trabecular meshwork maintain its structure and facilitate the outflow of aqueous humor from the eye by remodeling this porous tissue and preventing debris from occluding the outflow pathway. A reduction in cellularity and alterations in the architecture of the trabecular meshwork have been observed in glaucoma,\textsuperscript{52} and these changes may increase resistance to aqueous outflow, thereby elevating intraocular pressure and eventually damaging the optic nerve.\textsuperscript{51,53} Mutant myocilin that accumulates in the intracellular space may be toxic to trabecular-meshwork cells, initiating a cascade of events that begins with loss of function in these cells, which damages the outflow pathway and results in elevated intraocular pressure. The finding that aqueous humor outflow is reduced in patients with MYOC mutations supports this hypothesis.\textsuperscript{54} The development of animal models of myocilin-associated glaucoma\textsuperscript{30,55-56} provides new tools for exploring the effects of mutations in the myocilin gene on the structure and function of the outflow pathway at the tissue, cellular, and subcellular levels. In particular, these animal models will facilitate studies of the effects of MYOC mutations on the health and numbers of trabecular-meshwork cells and the

---

**Figure 4. The Optic-Nerve Head and Proposed Events Leading to Retinal Ganglion-Cell Death in Glaucoma.**

In the normal optic-nerve head and retina (Panel A), retinal ganglion-cell axons exit the eye through the lamina cribrosa, becoming myelinated only in the postlaminar region. Glia in the retina (e.g., Müller’s cells) and optic-nerve head (e.g., astrocytes and microglia) are quiescent (green). Increasingly elevated intraocular pressure puts stress on retinal ganglion cells, and glial cells become reactive (Panel B, red). Elevated intraocular pressure also leads to the production of a variety of substances, including tumor necrosis factor α, which in turn damage retinal ganglion-cell axons (dashed lines) at the lamina cribrosa. At this point there is no clinically detectable change in the cupping of the optic-nerve head. Damage to retinal ganglion-cell axons is followed by cell (soma) death through apoptosis (Panel C). Loss of retinal ganglion cells and axon fibers results in thinning of the nerve-fiber layer. The lamina cribrosa itself undergoes remodeling, becoming thicker while bowing posteriorly (blue arrows), with increased cupping of the optic-nerve head (black arrows). In the advanced stage of glaucoma (Panel D), apoptosis and neuro-inflammatory processes result in cell death and loss of most retinal ganglion cells and axons. The prelaminar tissue is substantially attenuated, and the lamina cribrosa becomes thinner and bowed more posteriorly (blue arrows), resulting in pronounced cupping of the optic-nerve head (black arrows).
such as brain-derived neurotrophic factor. Death from deprivation of neurotrophic factors can stress retinal ganglion cells and cause their loss. Axonal transport decreases if blood perfusion at the optic-nerve head is persistently reduced. Tissue hypoxia can induce the formation and accumulation of reactive oxygen species in the retina, and this accumulation causes cellular stress and malfunction. In glaucoma, proteins and lipids with oxidative modifications accumulate in the retina and optic-nerve head, and antioxidant treatments have some benefit in animal models. The use of microarray technology in animal models has shown that changes in the gene-expression profile of the retina occur rapidly in response to elevated intraocular pressure. These changes include decreased expression of many genes specific to retinal ganglion cells and increased expression of markers of hypoxia and glial activation.

Glial cells in the optic-nerve head (microglia and astrocytes) become activated in response to the elevated intraocular pressure in glaucoma (Fig. 4B). Activated astrocytes synthesize molecules that lead to degradation and remodeling of the extracellular matrix, and these changes can have biomechanical effects on the optic-nerve head that in turn increase stress on retinal ganglion-cell axons. In a mouse model of glaucoma, activated glial cells released tumor necrosis factor α (TNF-α), a proinflammatory cytokine. Deletion of the genes encoding TNF-α or its receptor increased the survival of retinal ganglion cells in this model. Intravitreal injection of TNF-α causes loss of retinal ganglion-cell axons and subsequently loss of entire cells, even in the absence of elevated intraocular pressure. These results suggest that TNF-α can be a mediator of damage of retinal ganglion-cell axons when intraocular pressure is elevated. The presence of TNF-α in human glaucomatous retina and optic-nerve head has been detected by immunohistochemical analysis. Collectively, this evidence suggests that glial activation and TNF-α are important mediators of damage to retinal ganglion-cell axons.

**Structural Changes**

Cupping of the optic-nerve head results from the loss of prelaminar tissue and posterior deformation of the lamina cribrosa. Three-dimensional histomorphometric studies of primates with experimentally induced glaucoma raised the possibility that one of the early changes in the structure of the optic-nerve head in glaucoma is the thickening — rather than thinning — of prelaminar tissue. This change is accompanied by microglial proliferation. Subsequently, the lamina cribrosa bows posteriorly (Fig. 4C). These changes in the lamina cribrosa, combined with the eventual loss of prelaminar tissue, make the cup larger and deeper. The biomechanical consequences of these changes are believed to strain retinal ganglion-cell axons, which further compromises their function. These morphologic findings are accompanied by changes in the composition of the extracellular matrix of the trabecular meshwork.
optic-nerve head, including increased synthesis of collagen IV, proteoglycans, adhesion molecules, and matrix metalloproteinases and a loss of gap-junction communication that accompanies astrocyte activation.\textsuperscript{83,86,94,95}

**Damage to Retinal Ganglion-Cell Axons**

Clinical observations have indicated that the optic-nerve head, and more specifically the lamina cribrosa, is the initial site of glaucomatous damage.\textsuperscript{96} In animal models, and presumably also in human glaucoma, damage to retinal ganglion-cell axons precedes the death of the cells\textsuperscript{97,98} (Fig. 4B and 4C). In the DBA2/J mouse strain, elevated intraocular pressure develops spontaneously at 7 to 9 months of age, and soon thereafter, axonal shrinkage and decreased retrograde transport occur, even though the soma of the retinal ganglion cells appears normal.\textsuperscript{99} In these mice, the retinal ganglion-cell axons proximal to the point of myelination survive, suggesting that damage to the axons occurs in an area that corresponds to the lamina cribrosa in primates.\textsuperscript{77,97} However, retinal ganglion cells survive for only about 1 to 2 months after axonal degeneration.\textsuperscript{77,97} Thus, the degradation of the retinal ganglion-cell axon and soma may involve separate mechanisms.\textsuperscript{100} In DBA/2 mice, damage to retinal ganglion-cell axons occurs despite the absence of the collagenous lamina cribrosa plates typically found in primates.\textsuperscript{101} This finding suggests that a cell-mediated mechanism underlies the damage, perhaps involving excessive synthesis of extracellular matrix material\textsuperscript{83,86,94,95} or elevation of intra-axonal calcium levels resulting from overexpression of ephrin-B2 (a receptor tyrosine kinase in glioma cells).\textsuperscript{102,103}

**Loss of Retinal Ganglion Cells**

Axonal damage and chronic stress result in the death of retinal ganglion cells. Most, if not all, of the loss of retinal ganglion cells in the glaucomatous retina occurs through apoptosis.\textsuperscript{104,105} Inhibition of apoptosis by deletion of the Bax gene in a mouse model of glaucoma almost completely rescues the retinal ganglion-cell soma, but axons are not preserved.\textsuperscript{100} By means of noninvasive direct imaging of apoptotic cell death,\textsuperscript{106} it has been possible to observe progressive loss of retinal ganglion-cell axons and cell bodies in a rat model of glaucoma. Coupled with thinning and further posterior bowing of the lamina cribrosa, apoptotic loss of the retinal ganglion cells results in a large, deep cup, as seen clinically in advanced glaucoma (Fig. 4D).

Retinal ganglion-cell death is not accompanied by prominent infiltration of mononuclear cells, although there is indirect evidence of inflammatory processes, as indicated by the presence of autoantibodies against retinal antigens in patients with glaucoma.\textsuperscript{81} Instead, glial cells phagocytose cellular debris and initiate a scar response after retinal ganglion-cell death. Inflammation-like glial activity is frequently observed in degenerative disorders of the central nervous system and is referred to as neuroinflammation, a process distinct from the adaptive immune response and more akin to a reaction of the innate immune system.\textsuperscript{107} In glaucoma, glial expression of major-histocompatibility-complex (MHC) class II molecules\textsuperscript{108} and synthesis of components of the complement cascade\textsuperscript{109,110} occur as retinal ganglion-cell death continues, and these processes may further contribute to the degeneration of retinal ganglion cells.

**Conclusions**

In glaucoma, a major cause of blindness, the ganglion-cell axons that make up the optic nerve are damaged by a variety of factors, only some of which are understood. The most important risk factor for glaucoma is elevated intraocular pressure. Because the optic-nerve damage in glaucoma is not yet amenable to direct treatment, we provide treatment for the only known risk factor that can be modified, elevated intraocular pressure. As more is understood about the molecular biology of the trabecular meshwork and optic nerve in health and disease, our ability to treat glaucoma will likely improve.

Supported in part by grants from the Marlene S. and Leonard A. Hadley Glaucoma Research Fund and Research to Prevent Blindness. Dr. Kwon received support from the Clifford M. and Ruth M. Altermatt Professorship, and Dr. Alward received support from the Frederick C. Blodi Chair.

Dr. Fingert reports receiving grant support from Alcon Research and holding several unlicensed patents related to gene discovery in glaucoma, and Dr. Alward reports holding an unlicensed patent for the diagnosis of MYOC mutations. No other potential conflict of interest relevant to this article was reported.

We thank Patricia Duffel, R.Ph., M.A., for her assistance with the preparation of the manuscript.
MECHANISMS OF DISEASE

45. Lam DS, Leung YF, Chua JK, et al. Truncations in the TIGR gene in individu-
46. Kim BS, Savinova OV, Reedy MV, et al. Targeted disruption of the myocilin gene (Myoc) suggests that human glaucoma-
47. Gould DB, Miceli-Libby L, Savinova OV, et al. Genetically increasing Myoc ex-
pression supports a necessary pathologic role of abnormal proteins in glaucoma.
48. Zhou Z, Volkhrt D. A cellular assay distinguishes normal and mutant TIGR/
receptor (PTS1R) to elevate intraocular pressure. Hum Mol Genet 2007;16:569-77.
50. Senatore V, Maluykova I, Farris R, et al. Expression of mutated mouse myocilin induces open-angle glaucoma in trans-
51. Alvarado J, Murphy C, Juster R. Trabec-
ular meshwork cellularity in primary open-
angle glaucoma and nonglaucomatous
52. Lötjen-Drecoll E, Rohren JW. Morphol-
53. Rodrigues MM, Speth GL, Sivalingam E, Weinreb S. Histopathology of 150 tra-
prediction: how optic nerve head biome-
odel remodeling. Prog Retin Eye Res 2000;19: 360;11
n engl j med 2009
N ENGL J MED 360;11 NEJM.ORG MARCH 12, 2009
Copyright © 2009 Massachusetts Medical Society. All rights reserved.

Copyright © 2009 Massachusetts Medical Society.